Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
ATTAIN-1 Trial Highlights: - Mean weight loss of ~12.4% over 72 weeks for patients on the highest dose - Participants lost an average of 25 pounds (11.1%) regardless of trial completion - Safety profile consistent with GLP-1 class
One case in the literature reports improvement in the clinical appearance and epidermal insulin signaling of AN in a 42-year-old woman with obesity and T2DM
USADA says it is prohibited under WADAs S0 category for unapproved substances and is not approved for human clinical use by any global regulatory authority
In practice, it seems better to tailor the choice to different patients, depending on the preference of the route of administration (oral vs injectable), the presence of intolerance or side-effects, and contraindications
Lilly is also leading this charge with retatrutide , a triple hormone receptor agonist that cut body weight by 26.6% on a placebo-adjusted basis at 68 weeks
We partnered up with a lab in England to get you pure, A+ grade, high-quality B12 that you can inject
